相关临床试验
226
22 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
6
2.6%
已完成
75
33.2%
尚未招募
16
7.1%
招募中
34
15.0%
暂停
1
0.4%
终止
12
5.3%
Unknown
81
35.8%
撤回
1
0.4%
暂无批准数据
- The TARTAN-HF trial found that 24.9% of diabetes patients with heart failure risk factors had previously undetected heart failure, compared to just 1% in the control group. - The study tested a simple GP-led screening pathway using NT-proBNP blood testing followed by cardiac ultrasound to identify undiagnosed heart failure in diabetic patients. - The screening approach enabled earlier identification of heart failure and initiation of guideline-directed therapy that could slow disease progression and improve patient outcomes. - Researchers are now analyzing how earlier detection could affect NHS care costs for at-risk diabetes patients.
- A 73-year-old man in Scotland became the world's first patient to receive gene therapy during heart bypass surgery, marking a breakthrough in cardiovascular treatment. - The PROTECT trial delivers TIMP-3 gene therapy directly to vein grafts during surgery to prevent vessel thickening and blockages that commonly cause bypass failure. - The innovative ex vivo treatment approach uses viral vectors to strengthen grafted vessels before implantation, potentially extending bypass durability beyond current standards. - This pioneering study represents over 20 years of translational research and opens new possibilities for gene therapy applications in cardiovascular medicine.
- The PHOENIX Study, one of the largest pharmacogenomics trials globally, will recruit up to 4,000 patients over two years to investigate how genetic profiles affect responses to 60 commonly prescribed NHS medications. - Around 15% of patients are expected to carry genetic variants that may reduce medication effectiveness or increase side effects, which currently go unnoticed without genetic testing. - Led by Professor Sandosh Padmanabhan at the University of Glasgow, the trial aims to provide real-world evidence for implementing precision medicine across Scotland's healthcare system. - Participants undergo simple genetic testing with results returned within days to help doctors determine optimal drug selection and dosing based on individual genetic makeup.
- The University of Glasgow's Living Laboratory for Precision Medicine has partnered with myDNA to generate real-world evidence supporting pharmacogenomics adoption in healthcare systems. - The collaboration aims to assess clinical benefits and cost-effectiveness of personalized drug selection based on individual genetic profiles, moving away from traditional "one-size-fits-all" medication approaches. - The partnership will focus on integrating pharmacogenomics into everyday clinical practice across Scotland and the NHS, with potential global impact for healthcare systems worldwide. - The initiative seeks to improve medication safety and efficacy for patients while contributing to significant cost savings for healthcare systems through precision medicine strategies.
